{"id":"NCT04250350","sponsor":"Eli Lilly and Company","briefTitle":"Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis","officialTitle":"An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-02-11","primaryCompletion":"2022-04-20","completion":"2022-06-22","firstPosted":"2020-01-31","resultsPosted":"2023-02-24","lastUpdate":"2023-02-24"},"enrollment":206,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"BIOLOGICAL","name":"Lebrikizumab","otherNames":["LY3650150","DRM06"]}],"arms":[{"label":"Lebrikizumab 250 mg","type":"EXPERIMENTAL"}],"summary":"This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to \\<18 years weighing ≥40 kilograms) with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.","primaryOutcome":{"measure":"Percentage of Participants Discontinued From Study Treatment Due to Adverse Events (AEs)","timeFrame":"Week 52","effectByArm":[{"arm":"Lebrikizumab 250 mg","deltaMin":2.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":70,"countries":["United States","Australia","Canada","Poland"]},"refs":{"pmids":["37318750"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/3TxlZTL9UMFNAZAnnCFnbk"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":206},"commonTop":["Dermatitis atopic","Nasopharyngitis","Covid-19","Upper respiratory tract infection","Headache"]}}